Sibopirdine

Sibopirdine, also known as EXP921, is a nootropic drug.[1]

Sibopirdine
Clinical data
ATC code
  • none
Legal status
Legal status
  • In general: unscheduled
Pharmacokinetic data
Bioavailabilitysus
Metabolismsus
Excretionsus
Identifiers
  • 5,5-bis(4-pyridylmethyl)-5H-cyclopenta[2,1-b:3,4-b']dipyridine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H18N4
Molar mass350.425 g·mol−1
3D model (JSmol)
  • c5cnccc5CC1(Cc3ccncc3)c2cccnc2-c4c1cccn4
  • InChI=1S/C23H18N4/c1-3-19-21(26-9-1)22-20(4-2-10-27-22)23(19,15-17-5-11-24-12-6-17)16-18-7-13-25-14-8-18/h1-14H,15-16H2 ☒N
  • Key:FJYRSJDIZKTXKB-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Synthesis
Sibopirdine synthesis: DuPont Merck Pharmaceutical Company; U.S. Patent 5,272,269 (1993).

4,5-Diazafluoren-9-one was the starting material.

See also

References
  1. Wong YN, Quon CY, Holm KA, Burcham DL, Frey NL, Huang SM, Lam GN (February 1996). "Pharmacokinetics and metabolism of EXP921, a novel cognitive enhancer, in rats". Drug Metabolism and Disposition. 24 (2): 172–9. PMID 8742228.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.